Receptor-mediated actions of renin and prorenin  by Oliver, J.A.
Kidney International (2006) 69       13
commentar y
Receptor-mediated actions of 
renin and prorenin
JA Oliver1
Renin can induce renal disease by generating angiotensin II and, 
thereby, increasing fibrosis. Huang et al describe a new mechanism of 
action whereby the renin–angiotensin system can also exert this effect. 
Direct activation of the renin/prorenin receptor in mesangial cells 
induced synthesis of TGF-β and profibrotic proteins. Hence, like other 
proteases such as thrombin, renin and prorenin are capable of receptor-
mediated cellular signaling.
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Th e renin–angiotensin system is a central 
regulator of extracellular fl uid volume 
and blood pressure. Fift y years aft er the 
discovery of renin, the landmark experi-
ments of Goldblat established that the 
system could also be responsible for 
disease (renovascular hypertension). 
Though tantalizing but controversial 
clinical observations by Laragh’s group 
suggested that the system, independ-
ently of renovascular hypertension 
and of hypertension itself, could have a 
widespread pathogenic role in the car-
diovascular system,1 the importance of 
the system in directly causing disease 
was fi rst fi rmly established in the kid-
ney. Brenner and coworkers,2 and others, 
showed that inhibition of angiotensin II 
(Ang II) action ameliorated the usually 
inexorable progression of glomerular 
sclerosis that characterizes many renal 
diseases. The recognition by Border 
and Noble3 that Ang II stimulation of 
extra-cellular matrix (ECM) protein 
synthesis in mesangial cells was, at least 
in part, mediated by TGF-β provided an 
explanation for the sclerosing action of 
angiotensin and further highlighted the 
importance of TGF-β in the pathogenesis 
of glomerulosclerosis.
Elucidation of the multiple roles of 
the renin–angiotensin system in normal 
homeostasis as well as its involvement 
in disease has been greatly facilitated by 
the availability of a variety of compounds 
that block its actions at diff erent sites. 
Researchers can make use of inhibitors 
of renin enzymatic action, inhibitors 
of angiotensin-converting enzyme, and 
competitive blockers for the receptors 
of Ang II, the last two of which are also 
available to the clinician. Use of these 
probes, in laboratory and clinical set-
tings, has established beyond doubt that 
inhibition of Ang II ameliorates a variety 
of renal and cardiovascular conditions 
characterized by progressive expansion 
of ECM and fi brosis.
Despite that use of inhibitors of the 
renin–angiotensin system is fi rmly estab-
lished in clinical practice, several aspects 
of the system still remain poorly under-
stood. Among the most signifi cant issues 
is the exact function of the renin precur-
sor circulating in plasma. Th is protein, 
termed ‘prorenin,’ contains a 43-amino 
acid peptide in the N-terminal of renin 
and, under normal conditions, lacks renin 
enzymatic activity (that is, it cannot gen-
erate angiotensin I from angiotensino-
gen), probably because the propeptide 
covers the enzymatic site and prevents 
access to angiotensinogen. Prorenin can 
be rendered enzymatically active by low 
pH (pH approximately 3.5; a reversible 
process) or by cleavage of the propep-
tide by a variety of proteases (kallikrein, 
trypsin, plasmin, and probably others, 
some of which are located in the kidney). 
Normally, the concentration of plasma 
prorenin exceeds that of plasma renin,4 
and although under most steady-state 
conditions renin and prorenin in plasma 
change in parallel, when renin secretion 
is acutely altered — for example, stimu-
lated by diuretic administration — the 
concentration of plasma active renin may 
suddenly exceed that of plasma prorenin, 
suggesting that prorenin is not stored in 
and secreted from renin-storage gran-
ules only. Further, in several conditions, 
such as pregnancy and diabetes mellitus 
with microvascular disease, prorenin in 
plasma is remarkably increased.5 The 
significance of these observations 
remains to be determined, and little 
is known about factors that regulate 
prorenin secretion.
Another aspect of the renin–angi-
otensin system that needs further study 
is a group of renin- and prorenin-
binding proteins,5 among which the 
most intriguing is a 350-amino acid 
membrane-associated polypeptide 
recently cloned from a human kid-
ney cDNA library by Nguyen and 
coworkers.6,7 As both renin and prorenin 
are capable of binding to it at high affi  nity, 
the authors named it the renin/prorenin 
receptor. Remarkably, upon receptor 
binding, renin’s enzymatic activity was 
increased, and when prorenin bound to 
the receptor, it showed enzymatic activ-
ity. Th is result suggested that the recep-
tor, using either renin or prorenin, may 
be important in generating angiotensin 
in the surface of the cell, perhaps attain-
ing concentrations of angiotensin much 
greater than those circulating in plasma 
(such a mechanism could explain why 
plasma concentrations of Ang II are in 
the picomolar range but binding affi  nities 
of this peptide to its receptors are in the 
nanomolar range)8. In addition, however, 
binding of renin/prorenin to the receptor 
in the presence of losartan led to intracel-
lular signaling (by activating the pathway 
of the mitogen-activated protein kinases 
extracellular signal–regulated kinase-
1 (ERK1) and ERK2), which suggests 
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that renin and prorenin may have novel 
mechanisms of action that are independ-
ent of angiotensin generation and are 
receptor mediated. Th e renin/prorenin 
receptor localized, as shown by immu-
nomicroscopy, to mesangial and vascular 
smooth muscle cells, and northern blot-
ting showed the receptor’s mRNA to be 
widely distributed.
In this issue, Huang et al.9 provide addi-
tional evidence that renin and prorenin 
have direct, receptor-mediated actions 
that appear to be independent of angi-
otensin generation. In the tradition of 
the authors’ laboratory, they carried out 
an impressive series of carefully designed 
experiments that yielded very interesting 
results. Th eir data can be summarized 
as follows. Using human renin and rat 
prorenin, they found that these proteins 
increased the synthesis of TGF-β in 
mesangial cells, cells previously found to 
contain renin/prorenin receptors.6 Th is 
eff ect was not altered by pharmacologi-
cal inhibitors of renin enzymatic action, 
inhibitors of the converting enzyme, 
or blockers of angiotensin receptor-I, 
which strongly suggests that the TGF-β-
stimulating eff ect of renin and prorenin 
is independent of the generation of Ang 
II. Renin also enhanced synthesis of 
fi bronectin, collagen I, and plasminogen 
activator inhibitor-1, and, where tested, 
these eff ects were partially blocked by 
an inhibiting antibody against TGF-β. 
Th e increase in TGF-β mRNA that was 
induced by renin could not be inhibited 
by losartan or enalaprilat (the active 
form of enalapril). To demonstrate that 
the eff ect of renin on TGF-β was receptor 
mediated, they transfected the cells with a 
small interfering RNA that decreased the 
mRNA of the renin/prorenin receptor; 
under these conditions renin was unable 
to increase the abundance of the mRNA 
for TGF-β. Because mesangial cells have 
been reported to contain all components 
of the renin–angiotensin system, Huang 
et al. considered the possibility that the 
observed eff ects of renin and prorenin 
were due to Ang II generation. Th ey pro-
vide several lines of evidence suggesting 
that this is very unlikely. Perhaps the 
most convincing results are that mRNA 
for angiotensinogen was not found in 
the mesangial cells and that Ang II was 
undetectable in the cell lysates. In sum, 
Huang et al found that receptor binding 
of renin and prorenin increased synthesis 
of TGF-β in mesangial cells and, at least 
in part by the action of this cytokine, 
increased the synthesis of fibronectin 
and collagen I, components of fi brotic 
ECM. Because blockade of Ang II is 
only partially effective in slowing the 
progression of glomerulosclerosis, these 
important results should stimulate addi-
tional research directly relevant to clini-
cal practice. Such work may profi t from 
previous research with other proteases 
such as thrombin, where it has long been 
recognized that receptor-mediated cel-
lular signaling is an important mecha-
nism regulating cardiovascular function 
and disease.10
Th at activation of the renin/prorenin 
receptor may be an important mecha-
nism of disease is supported by other 
observations. Transgenic rats express-
ing prorenin only in the liver had mark-
edly increased plasma prorenin and 
minimally elevated plasma renin activ-
ity.11 Interestingly, these animals did 
not have increased blood pressure but 
developed glomerulosclerosis, arterial 
wall thickening, and myocardial hyper-
trophy and fi brosis, observations con-
sistent with a direct pathogenic eff ect 
of prorenin. Recently, Ichihara et al.12 
used a decapeptide derived from the 43-
amino acid sequence of prorenin, which 
is attached to the N-terminal of renin. 
Th e peptide blocked the enzymatic acti-
vation of prorenin upon binding to the 
renin/prorenin receptor. Remarkably, 
when administered to diabetic rats, this 
peptide prevented the development of 
diabetic nephropathy without aff ecting 
the hyperglycemia. Th ese provocative 
results urgently require confi rmation and 
diff er from the fi ndings of Huang et al. in 
that the eff ect of prorenin appears to be 
dependent, at least in part, on its poten-
tial enzymatic activity, which is expressed 
when it is bound to the renin/prorenin 
receptor. It thus appears that prorenin, 
like renin, has angiotensin-dependent 
(that is, enzymatic) and direct, recep-
tor-mediated actions. Regardless of the 
relative contributions of these two mech-
anisms of action, it is clear that the roles 
of prorenin and of the renin/prorenin 
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Figure 1 | Potential pathogenic mechanisms of the renin–angiotensin system in 
mesangial cells. (a) Generation of angiotensin I by renin circulating in plasma (and subsequent 
generation of angiotensin II by converting enzyme) leads to angiotensin II receptor activation 
and synthesis of TGF-β by the cell. (b) Binding of renin and of prorenin to the renin/prorenin 
receptor leads to activation of the enzymatic action of prorenin and enhancement of renin’s 
catalytic activity. This may result in elevated concentrations of angiotensin (depicted as 
‘Angiotensin’ and meant to convey both angiotensin I and II) next to the cell surface. (c) As 
shown in the article by Huang et al., direct activation of the renin/prorenin receptor can also 
lead to TGF-β generation. Ang, angiotensinogen.
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receptor in normal physiology and dis-
ease require in-depth study. For example, 
generation of mice with genetic deletion 
of the renin/prorenin receptor gene is 
needed. Also, analysis of the actions of 
renin and of prorenin in mesangial cells 
from mice with genetic deletions of dif-
ferent components of the renin–angi-
otensin system may facilitate elucidation 
of the receptor-mediated (that is, angi-
otensin-independent) effects of renin 
and prorenin. Animals lacking angi-
otensin-I receptors, converting enzyme, 
or angiotensinogen are available, and 
their mesangial cells could be used.
In sum, a signifi cant body of evidence 
now indicates that activation of the 
renin–angiotensin system (Figure 1)can 
contribute to the induction and/or pro-
gression of renal and cardiovascular dis-
ease by at least three direct mechanisms 
(that is, independently of the hyperten-
sive eff ect of the system): (1) by direct 
activation of angiotensin receptors by 
Ang II; (2) by activation of the enzymatic 
action of prorenin and enhancement of 
renin’s catalytic activity upon binding 
of these proteins to the renin/prorenin 
receptor; and (3) as shown by Huang et al, 
by direct activation of the renin/prorenin 
receptor and generation of TGF-β. Need-
less to say, all these pathogenic mecha-
nisms raise the intriguing question of 
why normal physiological conditions in 
which the renin–angiotensin system is 
markedly and chronically activated (for 
example, with a low-sodium diet), and 
in which plasma renin and prorenin as 
well as Ang II are markedly elevated, are 
not associated with disease. Answering 
this important question would clarify the 
mechanisms by which these hormones 
contribute to disease.
Although pharmacological blockers of 
the renin–angiotensin system are clearly 
eff ective in many renal and cardiovascu-
lar diseases, their eff ectiveness is limited, 
and exciting novel therapeutic avenues 
are likely to open through research on 
receptor-mediated renin and prorenin 
actions. In addition, because inhibitors 
of the converting enzyme are currently 
among the most frequently prescribed 
antihypertensive medications, in view 
of the results of Huang et al., an analysis 
of the potential harmful eff ects of the 
markedly elevated concentrations of 
plasma renin caused by these drugs is 
urgently needed.
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Hypoxia-inducible factors: where, 
when and why?
JM Gleadle1, DR Mole1 and CW Pugh1
Hypoxia-inducible factor (HIF) is a family of transcription factors that 
regulate the homeostatic response to oxygen deprivation during 
development, physiological adaptation, and pathological processes such 
as ischemia and neoplasia. Our understanding of the function of different 
HIF isoforms is being advanced by understanding the processes that 
regulate their activity, learning where and when they are expressed and 
what genes they regulate.
Kidney International (2006) 69, 15–17. doi:10.1038/sj.ki.5000072
Hypoxia-inducible factor-1 (HIF-1) is an 
oxygen-regulated transcriptional complex, 
originally identifi ed by its role in the con-
trol of erythropoietin gene expression in 
response to changes in oxygen tension. Th e 
original HIF components were identifi ed 
aft er affi  nity purifi cation of proteins from 
hypoxic cells capable of binding the oxy-
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gen-regulated erythropoietin 3′ enhancer 
DNA sequence. Th e genes encoding these 
proteins were identifi ed as a novel α chain 
known as HIF-1α and a β chain that was 
found to be identical to the previously 
described aryl hydrocarbon receptor 
nuclear translocator, which is constitu-
tively expressed.1,2 Subsequent work has 
defi ned two further HIFα chains, HIF-2α 
and the much less well studied HIF-3α, 
one splice variant of which was originally 
identifi ed as inhibitory PAS protein 1.
Since the identifi cation of HIF-1, it has 
become clear that the HIF complexes have 
